Inhibikase Therapeutics

NasdaqCM:IKT Stock Report

Mkt Cap: US$23.0m

Inhibikase Therapeutics Financial Health

How is Inhibikase Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IKT's short term assets ($33.9M) exceed its short term liabilities ($4.5M).

Long Term Liabilities: IKT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IKT is debt free.

Reducing Debt: IKT currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IKT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IKT has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 71.8% each year.


Discover healthy companies